Company intelligence / Profile preview

Orasis Pharmaceuticals

Ponte Vedra, Florida, United Statesorasis-pharma.com ↗

Ownership: Private
Development stage: Commercial

Overview

QLOSI (pilocarpine hydrochloride ophthalmic solution 0.4%) received FDA approval and launched in the US in April 2025. In Phase 3 clinical trials (NEAR-1 and NEAR-2), the drug met primary and secondary endpoints by Day 8, achieving a statistically significant 3-line+ gain in distance-corrected near visual acuity and no loss of 1-line+ in distance visual acuity[8].

Therapeutic areas: Ophthalmology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

pilocarpine

Commercial

Indications: Presbyopia

Partnerships

Optus Pharmaceuticals (licensing agreement for Korean market with $18 million in milestone payments and double-digit royalty on sales)[2]

Beyond the preview

Go deeper on Orasis Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Orasis Pharmaceuticals.

Explore the full profile